Skip to main content
OpenTrials
Completed

NCT Number: NCT06769100

Exogenous Ketosis and Muscle Protein Synthesis During Exercise Recovery

An acute bout of resistance exercise stimulates muscle protein synthesis (MPS) rates for up to 24-48 hours, supporting muscle growth and repair. To optimize the anabolic effects of resistance exercise, the provision of dietary amino acids (i.e., proteins) is essential. Dietary protein intake provides the body with necessary amounts of essential and non-essential amino acids, which represent the building blocks for muscle proteins, enhancing anabolic muscle growth. The ingestion of dietary protein, such as whey protein, is well established to stimulate an increase in the rate of protein synthesis in skeletal muscle following resistance exercise. Research has demonstrated a dose-dependent relationship between protein intake and MPS rate, with 25 grams being the optimal dose to maximally stimulate MPS rates in younger adults with excess protein oxidized as a fuel source.

Determining whether this maximally stimulated MPS response can be further heightened during post-exercise recovery using non-protein dietary factors is yet to be explored. Recently, it has been shown that novel orally ingested ketone body supplements can stimulate MPS rates in younger adults at rest.

Ketone bodies (β-OHB) are lipid- derived molecules normally produced under conditions of glucose deprivation (i.e., fasting/starvation, or a low carbohydrate 'ketogenic' diet). However, these orally ingested ketone supplements rapidly increase blood ketone levels without the need for dietary restriction6. In vitro research showed that the combination of leucine and ketone bodies stimulated a 2-fold increase in MPS, compared to the leucine group alone, indicating synergistic effects of protein and ketone bodies on MPS. However, the effect of ketone supplementation, with and without dietary protein co-ingestion, on MPS rate during post-exercise recovery is yet to be investigated. If ketone bodies can amplify the anabolic response to dietary protein, they may provide a novel approach to maximizing muscle adaptation during post-exercise recovery.

Therefore, the purpose of this study is to evaluate the effects of ketone monoester intake on postprandial muscle protein synthesis rates when consumed alone and when co-ingested with an optimal dose (25 g) of whey protein during recovery after resistance exercise compared to 1) an optimal dose of whey protein (25 g), and 2) a control flavored water. It is hypothesized that muscle protein synthesis rates will be stimulated following the ingestion of the ketone body beverage. Further, muscle protein synthesis rates will be further enhanced when the ketone-containing beverage and an optimal dose are taken together.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ketosis Acid-Base Imbalance Acidosis Dietary Proteins Metabolic Diseases Muscle Protein Synthesis Nutritional and Metabolic Diseases Resistance Exercise

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

McGill University

Montreal, Quebec, H2W 1S4, Canada

About this study

A parallel group design will be used for this randomized double-blind, placebo-controlled study in healthy adults to investigate the effects of ketone monoester on myofibrillar protein synthesis rates during post-exercise recovery. There are 4 groups in this trial, including one ketone group (0.36g/kg body weight) (KET), one protein group (25 g whey protein) (PRO), a combination of ketone and protein (KET+PRO), and a placebo group (flavoured water) (CON). A total of 48 participants will be enrolled in this trial (n=12 per group).

The study will include a screening visit (visit 1), 10-repetition maximum (10-RM) testing (visit 2), where participants' 10-RM will be determined for the exercise protocol, and the experimental trial (visit 3).

During the experimental trials, participants will arrive to the laboratory in a fasted state, and a prime dose of the L-[ring-2H5]-phenylalanine will be administered followed by a continuous infusion at a rate 0.05 μmol/kg of body weight/min. Then, participants will perform a unilateral lower-body resistance exercise, consisting of 8 sets of 10 reps of unilateral leg extension at 90% of their 10-RM with 90 seconds rest in between sets. Following exercise, the nutritional treatment will be administered.

Arterialized blood will be collected at baseline and 13 postprandial timepoints across 9 hours for plasma amino acid, glucose, and insulin quantitation.

Additionally, changes in capillary blood β-HB concentration will be assessed throughout the trial by collecting capillary blood samples at baseline and 10 postprandial timepoints. Finally, muscle biopsy samples from both the exercised leg and the rested leg will be collected prior to beverage intake and at the 5-hour mark of the postprandial post-recovery period to assess myofibrillar protein synthesis rates.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult female or male participants who are 18-40 years of age (inclusive) BMI >18.5 and <30.0 kg/m2
  • Moderately active (i.e., ≥ 1 session of lower-body weightlifting /week for the previous 2 months).
  • Has maintained stable use of medication and supplements (which are not limited by the exclusion criteria), stable dietary and lifestyle habits, and stable body weight, for the last 3 months prior to screening and agree to maintain them throughout the study.
  • Be willing to entirely avoid alcohol consumption 48hr prior to the experimental test day.
  • Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.

Exclusion criteria

  • Females who are lactating or pregnant
  • Females using third-generation oral contraceptives (including: Desogen®, Ortho-Cept, Ortho-Cyclen, Ortho Tri-Cyclen) as these are known to affect protein metabolism in females.
  • Individuals with metabolic disorders including: Type I or Type II diabetes
  • Individuals with a history of thrombosis / cardiovascular disease
  • Individuals who use of anticoagulants
  • Individuals with musculoskeletal / orthopedic disorders
  • Individuals with knee injuries (i.e., ACL injuries).
  • Individuals who have used tobacco products within the last 6 months
  • Individuals with a history of neuromuscular problems
  • Chronic usage of medications known to modulate skeletal muscle metabolism (i.e. corticosteroids, hormone replacement therapy (HRT), and over-the-counter supplements including creatine monohydrate) in the last 6 months.
  • Individuals with allergies to milk proteins (whey or casein).
  • Individuals with lactose intolerance
  • Individuals with Phenylketonuria (PKU)
  • Previous participation in amino acid tracer studies.
  • Adherence to a vegetarian or vegan diet
  • Current use of ketone supplements or adherence to a ketogenic diet
  • Individuals who train more than ≥ 5 sessions of lower-body weightlifting /week for the previous 4 months

Treatment and study plan

Ketone Monoester (KET)

Dietary Supplement
  • Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester

Ketone Monoester + Whey Protein (KET+PRO)

Dietary Supplement
  • Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)
  • 25g Whey Protein
  • L-[ring-2H5]-phenylalanine tracer (enriched to 4%)

Whey Protein (PRO)

Dietary Supplement
  • 25g Whey Protein
  • L-[ring-2H5]-phenylalanine tracer (enriched to 4%)

Flavour matched placebo (CON)

Dietary Supplement
  • Flavoured water (non-caloric bitter + citrus flavours)

Resistance Exercise

Other
  • 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.

Primary outcomes

  1. Myofibrillar fractional synthesis rate

    Time frame: 0 - 5 hours in the postprandial period.

    Quantification of changes in basal myofibrillar fractional synthetic rate (%/hour) in the rested and exercised limbs.

Secondary outcomes

  1. Time-course data for plasma enrichments (in moles percent excess) of L-[ring-2H5]-phenylalanine

    Time frame: Baseline, 3 hours pre-prandial, and 5 hours into the postprandial period.

    Changes in plasma-free L-[ring-2H5]-phenylalanine enrichment measured at 14 time points (t = -180, -120, -60, 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 minute).

  2. Incremental area under the curve for total amino acid concentration

    Time frame: 3 hours pre-prandial to 5 hours postprandial

    Incremental area under the curve (iAUC) for plasma concentration of total amino acids (μmol/L) including: free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan, arginine, glutamine, glycine, alanine, serine, glutamic acid, aspartic acid, asparagine, tyrosine, cysteine, proline (combined), measured at baseline and across the 3-hour pre-prandial period and 5-hour postprandial period.

  3. Time-course data for total amino acid concentration

    Time frame: Baseline, 3 hours pre-prandial, and 5 hours into the postprandial period.

    Changes in plasma concentration of total amino acid concentration (μmol/L) including: free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan, arginine, glutamine, glycine, alanine, serine, glutamic acid, aspartic acid, asparagine, tyrosine, cysteine, proline (combined), measured at 14 time points (t = -180, -120, -60, 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 minute).

  4. Incremental area under the curve for essential amino acid concentration

    Time frame: 3 hours pre-prandial to 5 hours postprandial

    Incremental area under the curve (iAUC) for plasma essential amino acid concentration (μmol/L) including free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan (combined), measured at baseline and across the 3-hour pre-prandial period and 5-hour postprandial period.

  5. Time-course data for essential amino acid concentration

    Time frame: Baseline, 3 hours pre-prandial, and 5 hours into the postprandial period.

    Changes in plasma concentration of essential amino acid (μmol/L) including: free leucine, isoleucine, valine, histidine, lysine, methionine, phenylalanine, threonine, tryptophan (combined), measured at 14 time points (t = -180, -120, -60, 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 minute).

  6. Incremental area under the curve for leucine concentration

    Time frame: 3 hours pre-prandial to 5 hours postprandial

    Incremental area under the curve (iAUC) for plasma leucine concentration (μmol/L) measured at baseline and across the 3-hour pre-prandial period and 5-hour postprandial period.

  7. Time-course data for leucine concentration

    Time frame: Baseline, 3 hours pre-prandial, and 5 hours into the postprandial period.

    Changes in plasma concentration of leucine (μmol/L) measured at 14 time points (t = -180, -120, -60, 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 minute).

  8. Incremental area under the curve for glucose concentration

    Time frame: 3 hours pre-prandial to 5 hours post-prandial

    Plasma glucose concentration (mmol/L) and its corresponding incremental area under the curve (iAUC), measured at baseline and across the 3-hour pre-prandial period and 5-hour postprandial period.

  9. Time-course data for glucose concentration

    Time frame: Baseline, 3 hours pre-prandial, and 5 hours into the postprandial period.

    Changes in plasma concentration of glucose (mmol/L) measured at 14 time points (t = -180, -120, -60, 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 minute).

  10. Incremental area under the curve for insulin concentration

    Time frame: 3 hours pre-prandial to 5 hours post-prandial

    Incremental area under the curve (iAUC) for plasma concentration of insulin (pmol/L), measured at baseline and across the 3-hour pre-prandial period and 5-hour postprandial period.

  11. Time-course data for insulin concentration

    Time frame: Baseline, 3 hours pre-prandial, and 5 hours into the postprandial period.

    Changes in plasma concentration of insulin (pmol/L) measured at 14 time points (t = -180, -120, -60, 0, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 minute).

  12. Incremental area under the curve for β-HB concentrations

    Time frame: 1 hour pre-prandial to 5 hours postprandial

    Capillary blood β-OHB concentration (mmol/L) and its corresponding incremental area under the curve (iAUC) measured during the pre-prandial period and postprandial period.

  13. Time-course data for β-HB concentrations

    Time frame: 1 hour pre-prandial to 5 hours in the post-prandial period

    Changes in capillary blood β-OHB concentration (mmol/L) measured at 10 time points (t = -60, 0, 30, 60, 90, 120, 150, 180, 240, 300 minute).

  14. Changes in the phosphorylation status of anabolic signaling molecules

    Time frame: 0 and 5 hours of the postprandial period.

    Western blot analysis will be used to measure the changes in the basal phosphorylation status of anabolic signaling molecules, including p-mTORC1 (Ser2448), p-p70S6K (Thr389), p-Akt (Ser473), p-4E-BP1 (Thr37/46), and p-rpS6 (Ser240/244), p-ERK1(Thr202/Tyr204), and p-ERK2 (Thr185/Tyr187), in the exercised and the rested limbs.

Sponsors and collaborators

Lead sponsor

McGill University

Other

Registry information

Official study title

The Effects of Ketone Monoester Intake on Postprandial Myofibrillar Protein Synthesis Rates in Young Adults During Recovery Following an Acute Bout of Resistance Exercise

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 10, 2025
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.